ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 79 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $640,586 | -22.0% | 105,882 | 0.0% | 0.00% | – |
| Q2 2023 | $821,644 | +765.6% | 105,882 | +535.8% | 0.00% | – |
| Q1 2023 | $94,922 | -3.2% | 16,653 | 0.0% | 0.00% | – |
| Q4 2022 | $98,086 | +81.6% | 16,653 | 0.0% | 0.00% | – |
| Q3 2022 | $54,000 | -91.7% | 16,653 | -88.5% | 0.00% | – |
| Q2 2022 | $647,000 | -43.8% | 144,317 | -33.0% | 0.00% | – |
| Q1 2022 | $1,151,000 | -65.1% | 215,513 | -4.0% | 0.00% | -100.0% |
| Q4 2021 | $3,300,000 | -28.2% | 224,431 | +2.2% | 0.00% | -50.0% |
| Q3 2021 | $4,593,000 | +98.4% | 219,655 | +67.9% | 0.00% | +100.0% |
| Q2 2021 | $2,315,000 | -17.5% | 130,815 | +14.2% | 0.00% | 0.0% |
| Q1 2021 | $2,806,000 | -24.4% | 114,503 | +4.4% | 0.00% | 0.0% |
| Q4 2020 | $3,714,000 | +180.7% | 109,713 | +107.5% | 0.00% | 0.0% |
| Q3 2020 | $1,323,000 | -27.0% | 52,876 | -1.6% | 0.00% | 0.0% |
| Q2 2020 | $1,813,000 | – | 53,722 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |